Overview: Cannabinoids Screen TestIntroduction: The Cannabinoids Screen Test detects marijuana use, indicating substance abuse causing altered behavior or memory issues. Following 2023 SAMHSA guidelines, it uses chromatography for high sensitivity, aiding in drug screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in toxicology for patients with suspected substance abuse.
Other Names: Cannabinoids Assay, Marijuana Screen Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Cannabinoid testing began in the 1970s with urine screens. Chromatography methods emerged in the 1980s, and by the 2000s, gas chromatography-mass spectrometry improved detection accuracy.
Purpose: Detects marijuana use, guides substance abuse treatment, and monitors compliance in patients with altered behavior or memory issues.
Test Parameters: 1. Delta-9-THC Metabolites
Pretest Condition: No fasting required. Collect urine, serum, plasma, or hair at any time. Report symptoms like altered behavior or history of substance use, and list medications.
Specimen: 5-20 mL urine (sterile container), 2-5 mL serum (SST), 2-4 mL plasma (EDTA), or 1-2 g hair (sterile container). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document substance use history, altered behavior, or occupational concerns. Include current medications, especially psychotropics.
Consent: Written consent required, detailing the tests purpose, implications for substance abuse treatment, and potential legal or occupational consequences.
Procedural Considerations: Uses chromatography (e.g., GC-MS) to detect delta-9-THC metabolites. Results are available in 1-2 days, supporting rapid clinical decisions.
Factors Affecting Result Accuracy: Cross-reactivity with certain medications may cause false positives. Improper storage can degrade samples.
Clinical Significance: Positive results confirm marijuana use, prompting addiction treatment or monitoring. Negative results may require confirmatory testing.
Specialist Consultation: Consult a toxicologist for result interpretation. An addiction specialist referral is advised for treatment planning.
Additional Supporting Tests: Urine drug panel, blood alcohol test, or opioid screen to assess polysubstance use.
Test Limitations: False positives may occur with hemp products. Results require clinical correlation with history.
References: SAMHSA Drug Testing Guidelines, 2023; Journal of Analytical Toxicology, Moeller MR, 2022.
